Cibc World Market Inc. Has $43.66 Million Holdings in Stryker Co. (NYSE:SYK)

Cibc World Market Inc. raised its holdings in shares of Stryker Co. (NYSE:SYK) by 7.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 121,249 shares of the medical technology company’s stock after acquiring an additional 8,029 shares during the period. Cibc World Market Inc.’s holdings in Stryker were worth $43,656,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Capital Planning LLC grew its holdings in Stryker by 3.6% in the fourth quarter. Capital Planning LLC now owns 841 shares of the medical technology company’s stock worth $304,000 after purchasing an additional 29 shares during the period. Alhambra Investment Management LLC grew its holdings in Stryker by 1.5% in the fourth quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock worth $719,000 after purchasing an additional 29 shares during the period. Avestar Capital LLC grew its holdings in Stryker by 1.1% in the third quarter. Avestar Capital LLC now owns 2,948 shares of the medical technology company’s stock worth $1,065,000 after purchasing an additional 31 shares during the period. Union Savings Bank grew its holdings in Stryker by 1.0% in the fourth quarter. Union Savings Bank now owns 3,162 shares of the medical technology company’s stock worth $1,138,000 after purchasing an additional 31 shares during the period. Finally, Patrick M Sweeney & Associates Inc. grew its holdings in shares of Stryker by 1.5% during the third quarter. Patrick M Sweeney & Associates Inc. now owns 2,194 shares of the medical technology company’s stock valued at $793,000 after buying an additional 32 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Down 0.2 %

NYSE:SYK opened at $390.48 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company’s 50 day moving average is $376.55 and its two-hundred day moving average is $362.18. The company has a market cap of $148.86 billion, a PE ratio of 50.32, a P/E/G ratio of 2.68 and a beta of 0.95.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.86%. During the same quarter in the previous year, the firm earned $3.46 earnings per share. Analysts anticipate that Stryker Co. will post 13.53 EPS for the current year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a dividend of $0.84 per share. This is a positive change from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. Stryker’s dividend payout ratio is presently 43.30%.

Insider Transactions at Stryker

In related news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. BTIG Research increased their price target on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. UBS Group increased their price target on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Evercore ISI increased their price target on shares of Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Stifel Nicolaus increased their price target on shares of Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a report on Wednesday. Finally, StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research report on Thursday. Five investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and a consensus target price of $416.40.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.